Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 3/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9563436 | 0.75 | LPAR1 (0.42) | BTN3A1LMNAFDPSPGK1PGK2 | |
| SCHEMBL2455845 | 0.75 | BTN3A1 (0.39) | BTN3A1LMNAFDPS | |
| Phosphoric Acid SCHEMBL5963671 | 0.74 | BTN3A1 (0.33) | BTN3A1LMNAFDPSPGK1PGK2 | |
| SCHEMBL28909650 | 0.69 | HMGCR (0.37) | BTN3A1LMNAPGK1PGK2 | |
| SCHEMBL28909659 | 0.69 | HMGCR (0.37) | BTN3A1LMNAHSD17B10TDP1 | |
| Phosphoric Acid SCHEMBL3215377 | 0.65 | LAP3 (0.39) | BTN3A1FDPSPGK1PGK2HSD17B10 | |
| Phosphoric Acid SCHEMBL3211434 | 0.65 | LAP3 (0.39) | BTN3A1FDPSPGK1PGK2HSD17B10 | |
| Phosphoric Acid SCHEMBL5963652 | 0.65 | LAP3 (0.39) | BTN3A1FDPSPGK1PGK2HSD17B10 | |
| Phosphoric Acid SCHEMBL3232688 | 0.65 | LAP3 (0.39) | BTN3A1FDPSPGK1PGK2HSD17B10 | |
| Phosphoric Acid SCHEMBL3221337 | 0.65 | LAP3 (0.39) | BTN3A1FDPSPGK1PGK2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017596-B2 | Phosphonates useful as modulators of T-γ-9-δ-2 activity | INNATE PHARMA, S.A. (FR) | 2011-09-13 | — | — | US | disclosed |
| US-20100204184-A1 | Phosphonates useful as modulators of T-gamma-9-delta-2 activity | LABORATOIRES MAYOLY SPINDLER (FR) | 2010-08-12 | — | — | US | disclosed |
| US-20060241087-A1 | Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity | MONTERO JEAN-LOUIS | 2006-10-26 | — | — | US | disclosed |
| EP-1453840-A1 | PHOSPHONATES USEFUL AS MODULATORS OF T-GAMMA-9-DELTA-2 LYMPHOCYTE ACTIVITY | Laboratoire Mayoly Spindler (FR) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003050128-A1 | PHOSPHONATES USEFUL AS MODULATORS OF T $G(G)9$G(D)2 LYMPHOCYTE ACTIVITY | LABORATOIRE MAYOLY SPINDLER (FR) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204184-A1 | Phosphonates useful as modulators of T-gamma-9-delta-2 activity | CD4, PRKCD, PRKCZ | BTN3A1 417/4885LMNA 2695/4885FDPS 2881/4885 |
| US-20060241087-A1 | Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity | CD4, GNG2, PLCG2 | BTN3A1 797/4885LMNA 3304/4885FDPS 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.